ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PHAR Pharming Group NV

10.00
0.3118 (3.22%)
10 May 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Pharming Group NV NASDAQ:PHAR NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.3118 3.22% 10.00 4.77 10.85 10.20 9.40 9.78 2,927 21:00:20

Pharming Group to report second quarter and first half 2023 financial results on August 3

13/07/2023 7:00am

PR Newswire (US)


Pharming Group NV (NASDAQ:PHAR)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Pharming Group NV Charts.

LEIDEN, The Netherlands, July 13, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.

Pharming Group Logo

Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 EDT on August 3, 2023.

Dial in details for the presentation are detailed below.

Webcast Link:
https://webcast.openbriefing.com/pharming1h23/

Conference Call Dial-in Details:
Netherlands: +31 85 888 7233 
United States (Local): +1 646 664 1960 
United Kingdom (Local): +44 20 3936 2999 
Global Dial-In Numbers
Access Code: 760288

About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696

Heather Robertson, Investor Relations & Corporate Communications Manager
E: investor@pharming.com

FTI Consulting, London, UK 
Victoria Foster Mitchell/Alex Shaw/Amy Byrne 
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands 
Leon Melens 
T: +31 6 53 81 64 27
 E: pharming@lifespring.nl

Logo- https://mma.prnewswire.com/media/2074393/Pharming_Group_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/pharming-group-to-report-second-quarter-and-first-half-2023-financial-results-on-august-3-301875863.html

Copyright 2023 PR Newswire

1 Year Pharming Group NV Chart

1 Year Pharming Group NV Chart

1 Month Pharming Group NV Chart

1 Month Pharming Group NV Chart

Your Recent History

Delayed Upgrade Clock